<DOC>
	<DOCNO>NCT00424164</DOCNO>
	<brief_summary>RATIONALE : Lapatinib may stop growth tumor cell block enzymes need cell growth . Estrogen cause growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block use estrogen tumor cell . Giving lapatinib together tamoxifen may effective treatment breast cancer . PURPOSE : This randomized phase I trial study side effect lapatinib tamoxifen treat patient advance metastatic breast cancer .</brief_summary>
	<brief_title>Lapatinib Tamoxifen Treating Patients With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pharmacokinetics lapatinib ditosylate tamoxifen citrate patient advance metastatic breast cancer . Secondary - Assess safety regimen patient . - Determine relationship drug exposure adverse event biological modification regimen patient . - Assess antitumor activity regimen patient measurable disease . OUTLINE : This open-label , randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral tamoxifen citrate day 1-28 course 1 . In subsequent course , patient receive oral tamoxifen citrate oral lapatinib ditosylate day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Arm II : Patients receive oral lapatinib ditosylate day 1-14 course 1 . In subsequent course , patient receive oral lapatinib ditosylate oral tamoxifen citrate day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . In treatment arm , blood collect periodically course 1 2 pharmacokinetic study . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced metastatic breast cancer Progressive disease aromatase inhibitor therapy Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive tumor Patients stable brain metastasis ( i.e. , neurological symptom corticosteroid treatment ) eligible PATIENT CHARACTERISTICS : Male female Menopausal status specify ECOG performance status 02 Life expectancy ≥ 12 week Neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ AST and/or ALT &lt; 3 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN Bilirubin &lt; 1.5 time ULN Clinically normal cardiac function ( i.e. , LVEF normal MUGA ECHO ) No current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis , stable chronic live disease ) No ischemic heart disease within past 6 month Normal 12lead ECG No active uncontrolled infection No serious illness medical condition , include follow : Hypercalcemia Malabsorption syndrome Chronic alcohol abuse Hepatitis HIV Cirrhosis Able swallow retain oral medication No psychological , familial , sociological , geographical condition potentially hamper study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 day since prior concurrent inducer inhibitor CYP3A4 , include follow : Rifabutin Clarithromycin Cyclosporine Voriconazole Fluoxetine Paroxetine Midazolam Isoniazid Dihydralazine Digitoxin Coumadin Phenytoin Verapamil Diltiazem Herbal constituent ( e.g. , bergamottin glabridin ) At least 2 week since prior aromatase inhibitor Aromatase inhibitor adjuvant and/or metastatic setting allow At least 1 year since prior tamoxifen citrate No concurrent anticancer therapy investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>